Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-FAST in advanced or metastatic non-small cell lung cancer
PACTR202211687583152Phase 2Recruiting
- Sponsor
- Roche
- Start
- Jan 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, bevacizumab, carboplatin, pemetrexed, divarasib and 1 more in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jan 2023; status: recruiting.
02
Drugs
atezolizumabbevacizumabcarboplatinpemetrexeddivarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on PACTR202211687583152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202211687583152.